Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96C36
UPID:
P5CR2_HUMAN
Alternative names:
-
Alternative UPACC:
Q96C36; A8K798; Q7Z515; Q9Y5J4
Background:
Pyrroline-5-carboxylate reductase 2 is a pivotal enzyme in proline biosynthesis, catalyzing the conversion to proline, essential for cellular functions. It exhibits a preference for NADP but shows higher catalytic efficiency with NADH, playing a crucial role in the cellular response to oxidative stress.
Therapeutic significance:
Linked to Leukodystrophy, hypomyelinating, 10, a severe neurologic disorder, understanding Pyrroline-5-carboxylate reductase 2's role could unveil new therapeutic strategies, highlighting its importance in disease mechanisms.